SGH Medical Technology Fund

SG Hiscock has launched a new fund - the SGH Medical Technology Fund - that will invest in a mix of established and start-up medical technology companies. The fund will invest in between 40 to 60 listed or unlisted opportunities in Australia and New Zealand.

The fund will have a social impact focus and will look to provide investors with long-term capital growth by finding and investing in medical technology companies where innovation plays a crucial role in improving global health and economic outcomes.

“Australia's history of medical breakthroughs includes penicillin, the bionic ear, ultrasounds, spray-on skin, and the cervical cancer vaccine. In addition, there are many research facilities in Australia which are recognised as medical centres of excellence at a global level," portfolio manager Rory Hunter said.

The fund will be run by the SGH Emerging Companies Team and SG Hiscock has established the SGH Medical Technology Advisory Board, made up of industry leading experts, to guide the fund. SG Hiscock will also establish a registered charitable foundation which will be funded by 10% of net revenue from the fund, including performance fees.

SG Hiscock & Company SGH Medical Technology Fund Launched on 29 June 2021 Designed for wholesale, retail and institutional investors. Find out more This report is informational only in nature. Industry Moves neither recommends nor endorses this product/service.